The Mirror: Gemma Collins is feeling great after losing 3 ½ stone
Reality star Gemma Collins opens up to The Mirror about her 3.5 stone weight loss journey with Yazen. Find out how she's keeping it off for good.

Gemma Collins is feeling great after losing 3.5 stone with Yazen.
Reality TV star, Gemma Collins, has shared a motivating update on her impressive weight loss journey with Yazen in the Mirror newspaper. After successfully losing three and a half stone, Gemma is now adjusting her approach following a health concern earlier this year.
The star recently experienced a gallbladder attack, which led to a pause in her weight management programme. However, she was quick to clarify her commitment, expressing her confidence in her medical team.
"I had to stop the medication for a bit because I had a gallbladder attack in August, but my team of doctors at Yazen assured me that it's not actually linked to Mounjaro," Gemma confirmed.
Gemma is feeling good and is happy with the results.
"I've lost about 3½st and kept it off. I just feel good," she said, adding that her goal is fundamentally health-focused: "I'm never going to look stick thin. I don't want to look stick thin. It's not who I am. But it's about being healthier. So it's all going in the right direction."
She attributes her success to the support and the fundamental change in her eating habits.
"I'll always love my food, but Yazen’s support and medication stops me," she commented.
Gemma understands that it’s not only about the physical changes but also the mental aspect of her transformation:
"I've been big for a long time. And actually at first I was so shocked by the rapid weight loss. It was weird for my mind. When I looked in the mirror, I looked so different. And I was like, 'Woah, am I ready for this?'”
Read the full article at The Mirror
More news
Yazen achieved record-breaking growth in 2025, doubling its revenue.
In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.







